a
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
Investor insights
Funding rounds participated in
$1.1B sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2008
Funding rounds raised
Total raised
$1.1B
from investors over 1 rounds
a
argenx raised $1.1B on August 18, 2023